You may leave me a review on these links:

Dr Laurence Krieger

  • MBChB (Hons) FRACP
  • Medical Oncologist
  • Spoken languages English


Research interests

Urogenital clinical trials

Professional memberships

  • EVIQ
  • ESMO
  • ASCO

Publications and affiliations

  • KEYNOTE-057: Open Label, Multicentre, Phase 2 Study of Pembrolizumab Monotherapy for the Treatment of Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin (BCG): Arjun VB, Girish SK, Krieger LE, et al. The Lancet Oncology (accepted for publication May 2021)
  • Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castrate Resistant Prostate Cancer: Analysis from the Phase II TRITON 2 Study: Abida W, Campbell D, Patnaik A, Shapiro JD, Krieger LE, Chowdhury et al; Clin Cancer Res 2020 Jun 1;26(11):2487-2496. Doi: 10.1158/1078-0432.CCR-20-0394
  • Rucaparib in Men with Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA 2 Gene Alteration: Abida W, Patnaik A, Shapiro J, Krieger LE, Chowdhury Set al: J Clin Oneal. 2020 Nov 10;38(32):3763-3722. Doi:10.1200/JCO.20.01035
  • Treatment Selection for First-Line Metastatic Renal Cell Carcinoma in Australia: Impact of new therapy options: Schmidt A, Azad A, Goh J, Harris C, Joshua AM, Weickhardt A, Krieger L: Asia Pac J Clin Oncology. 2019 Nov;15 Supp 10:3-10 DOI: 10.111/acjo.13289
  • Nonmetastatic, Castration Resistant Prostate Cancer and Survival with Darolutamide: Fizazi K, Shore N, Temmela TL, Smith MR et al. N Eng J Med 2020 Sep 10;383(11):1040-1049. Doi 1056/NEJMoa20001342 (Member of the ARAMIS study investigators)